Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission

About this update from Zelluna Asa

[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"text","content":"Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the fourth quarter and full year 2025.","length":275,"tagName":"p"},{"type":"text","content":"Webcast scheduled for 12 February 2026, at 08:30 (CET). Link to webcast here.","length":78,"tagName":"p"},{"type":"text","content":"Operational Highlights Q4 2025","length":30,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CTA submitted: On 17 December 2025, Zelluna submitted its first Clinical Trial Application (CTA) to the UK MHRA for ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy. Initial Phase I clinical data are expected to emerge from mid-2026.","length":259,"tagName":"p"}]},{"val":[{"type":"text","content":"First GMP batch completed: On 12 December 2025, the first GMP batch of ZI-MA4-1 was manufactured and quality-tested for use in the upcoming clinical trial.","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical data published: Compelling preclinical data for ZI-MA4-1 published in Immunotherapy Advances in December 2025.","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Capital raise: NOK 58.2 million raised in November 2025 through private placement and retail offering.","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":653,"olType":false},{"type":"text","content":"Financial Highlights Q4 2025","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total operating expenses: NOK 35.4 million (FY25: NOK 143.8 million)","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Total loss: NOK 34.6 million (FY25: NOK 140....

More updates from Zelluna Asa